Cerebrolysin vs IGF-1 LR3
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Side-by-Side Comparison
| Aspect | Cerebrolysin | IGF-1 LR3 |
|---|---|---|
| Dose Range | 2150 mg–4300 mg | 20 mcg–100 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–2 weeks | 4–6 weeks |
| Route | intramuscular | subcutaneous |
| Mechanism | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. |
| Typical Dosage | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. |
| Administration | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. |
| Side Effects | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. |
| Best For |
What They Have in Common
Cerebrolysin, IGF-1 LR3 are both commonly used for:
Key Differences
Unique to Cerebrolysin:
Unique to IGF-1 LR3:
Which Has Stronger Evidence?
- Recovery & Healing: Cerebrolysin has stronger research support.
| Goal | Cerebrolysin | IGF-1 LR3 |
|---|---|---|
| Recovery & Healing | high | medium |
Key Studies
Cerebrolysin
- Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice.
Neurochemical research, 2025
- Is Cerebrolysin Useful in Psychiatry Disorders?
Biomedicines, 2025
- Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway.
Molecular brain, 2025
IGF-1 LR3
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
American journal of physiology. Endocrinology and metabolism, 2025
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.
International journal of biological macromolecules, 2025
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
Journal of developmental origins of health and disease, 2023
Ready to Learn More?
Looking for trusted sources?